Prolia (Denosumab) Cost in Oregon 2026

What Is the Cash-Pay Price of Prolia in Oregon in 2026?

Oregon retail pharmacies list brand Prolia at roughly $1,500 per 60 mg prefilled syringe in 2026, matching Amgen's published wholesale acquisition cost. Because one injection covers six months of therapy, a patient paying fully out of pocket spends approximately $3,000 per year. Prices vary by pharmacy, and GoodRx or similar discount cards rarely cut the cost of specialty biologics like denosumab by more than a few percent at retail counters.

Denosumab is a fully human monoclonal antibody that binds RANKL (receptor activator of nuclear factor kappa-B ligand), stopping osteoclast-mediated bone resorption [1]. The mechanism is distinct from bisphosphonates, which makes it a preferred option for patients with chronic kidney disease or those who cannot tolerate oral agents. FDA approved Prolia in June 2010 for postmenopausal women with osteoporosis at high fracture risk [2].

The landmark FREEDOM trial (N=7,868) demonstrated that denosumab 60 mg every six months reduced new vertebral fractures by 68% over 36 months compared with placebo (P<0.001), and cut hip fractures by 40% (P<0.04) [3]. Those numbers help justify the drug's price for payers and patients who can access coverage. The Endocrine Society's 2019 pharmacological management guideline recommends denosumab as a first-line option for postmenopausal osteoporosis, particularly when renal impairment precludes bisphosphonate use [4].

One practical point: because denosumab suppresses bone turnover while it is actively present in the body, missing or delaying a dose beyond two months past the scheduled date substantially raises rebound vertebral fracture risk [5]. That discontinuation risk is a cost consideration in its own right. Patients who cannot guarantee every-six-month access should discuss switching to a bisphosphonate or zoledronic acid annually with their prescriber.

Does Oregon Medicaid (OHP) Cover Prolia?

Oregon Health Plan (OHP), the state's Medicaid program, covers Prolia for qualifying diagnoses with a prior authorization (PA) requirement. Approved indications include postmenopausal osteoporosis, osteoporosis in men at high fracture risk, glucocorticoid-induced osteoporosis, and bone loss associated with certain cancer therapies (at the 120 mg Xgeva dose, a separate product). For the 60 mg Prolia indication, the typical PA criteria require a documented DXA T-score at or below -2.5, or a documented fragility fracture, along with evidence that a bisphosphonate trial was either completed or is contraindicated [6].

Oregon Medicaid coordinates benefits through coordinated care organizations (CCOs). The PA decision is made at the CCO level, so the exact criteria and turnaround times differ slightly across the state's 16 CCOs. Patients in the Portland metro area served by one CCO may face different documentation requirements than those in rural southern Oregon served by another. A prescriber's office familiar with OHP PA workflows can usually submit a complete PA request in one visit.

The Centers for Medicare and Medicaid Services requires state Medicaid programs to cover all FDA-approved drugs from manufacturers who sign rebate agreements, subject to utilization-management tools such as PA [7]. Amgen participates in the Medicaid Drug Rebate Program, which means OHP cannot simply exclude denosumab without a legitimate clinical basis.

For dual-eligible patients (Medicare Part D plus OHP), Medicare Part D is the primary payer. Under Medicare Part D, Prolia typically sits on Tier 5 (specialty), with a 25 to 33 percent coinsurance during the coverage gap phase. OHP wraps around Part D cost-sharing for dual-eligible individuals, so net out-of-pocket cost for many dual-eligibles is $0 to $10 per injection [8].

Which Commercial Insurance Plans Cover Prolia in Oregon?

Most commercial plans sold on Cover Oregon (now the federally facilitated Marketplace) and large employer plans in the state do cover Prolia, but the benefit placement varies widely. About 60 percent of commercial formularies place denosumab on a specialty tier requiring 20 to 33 percent coinsurance before the out-of-pocket maximum is met. A 2023 analysis of Medicare Part D formularies found that 92 percent of plan sponsors covered denosumab, though tier placement and cost-sharing differed substantially [9].

Key steps for Oregon patients with commercial insurance:

1. Confirm whether your plan covers the drug under the pharmacy benefit or the medical benefit. Some plans administer Prolia as a physician-administered injectable under the medical benefit (Part B analog), which carries a different cost-sharing structure than a pharmacy-dispensed specialty medication.
2. Request a prior authorization if required. Commercial PA criteria closely resemble OHP criteria: DXA evidence or fracture history, plus documentation of osteoporosis diagnosis by ICD-10 code M81.0 or equivalent.
3. Apply the Amgen savings card (see below) if your plan is commercial and not a government program.

The Oregon Insurance Division enforces the Affordable Care Act's out-of-pocket maximum rules, which cap total cost-sharing at $9,450 for an individual plan in 2025 [10]. Once that cap is hit, Prolia injections for the rest of the year cost $0. Patients with multiple specialty medications often reach the OOP max before mid-year.

How Does the Amgen Prolia Savings Card Work in Oregon?

The Amgen SupportPlus program (also called the Prolia Co-pay Card) offers eligible commercially insured patients a $0 copay per dose, subject to an annual cap that Amgen periodically revises. As of early 2025, the cap sat at $13,000 per calendar year, which is more than enough to cover two injections annually for most patients [11].

Eligibility rules are straightforward. The patient must be covered by a commercial insurance plan (not Medicare, Medicaid, TRICARE, or any other federal or state government program). The prescribing provider must enroll the patient through the Amgen SupportPlus portal or by calling 1-800-272-9376. Oregon residents can use any in-network specialty pharmacy or have the injection administered in a provider's office with the card applied at the point of dispensing.

Patients who are uninsured or underinsured and do not qualify for the commercial card may apply to the Amgen Safety Net Foundation (ASNF), which provides free medication to qualifying low-income patients across Oregon. Income eligibility is generally at or below 500 percent of the federal poverty level, though the program reviews applications case by case [12].

One documentation tip: Amgen's enrollment team requires proof of insurance card, a copy of the prescription, and a completed HIPAA authorization form. Oregon providers who administer the injection in-office should keep the co-pay card number on file and submit it directly to Amgen for reimbursement within 90 days of the injection date.

Is Compounded Denosumab Legal in Oregon?

Compounded denosumab is available through state-licensed 503A compounding pharmacies in Oregon. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, a licensed pharmacist may compound a drug that is not commercially available in the needed strength, dosage form, or quantity, provided it is made pursuant to a valid patient-specific prescription [13]. Because Prolia is a commercially available biologic, FDA and many compounding-law experts have noted that compounding copies of FDA-approved biologics sits in a legal gray zone. FDA guidance published in 2018 stated that copying an approved drug without a documented clinical difference could be considered inappropriate under 503A [14].

Oregon's Board of Pharmacy, under ORS Chapter 689, licenses and inspects 503A compounding pharmacies operating in the state. The Board has not issued a specific prohibition on compounded denosumab as of the date of this article's review, but practitioners should be aware that FDA enforcement discretion can change. Patients and prescribers should verify current Board of Pharmacy status for any Oregon compounding pharmacy before dispensing a compounded biologic [15].

The practical cost picture is compelling. Where a licensed 503A pharmacy does prepare compounded denosumab for a specific patient under a valid prescription, the cost to the patient may be substantially below the $1,500 brand price, sometimes approaching little to no cost depending on pharmacy pricing and the patient's specific access program. That price differential is what drives patient interest, but the clinical and regulatory risks warrant an explicit conversation with the prescriber.

From a clinical safety standpoint, compounded biologics do not undergo the same immunogenicity testing as FDA-approved reference products. A 2021 FDA advisory communication noted that compounded versions of biologics may carry different immunogenic profiles than the reference product [16]. Denosumab's mechanism depends on highly specific RANKL binding, and even minor formulation differences could affect efficacy or tolerability.

Can I Get Prolia Via Telehealth in Oregon?

Yes. Oregon law permits telehealth prescribing of Schedule-exempt prescription medications, including Prolia, without a mandatory in-person visit, provided an established provider-patient relationship exists or is formed through a synchronous audio-video encounter [17]. The Oregon Medical Board's telemedicine policy, updated in 2021, requires that the prescribing clinician be able to conduct a clinical evaluation sufficient to make a diagnosis and determine that the requested treatment is appropriate.

For Prolia specifically, a telehealth prescriber would typically review the patient's most recent DXA scan report (sent electronically), medication history, renal function labs (eGFR), and fracture history. The prescription is then sent electronically to a specialty pharmacy, which ships the prefilled syringe to a local provider's office, infusion center, or in some arrangements directly to the patient for self-administration. The FDA prescribing information for Prolia notes that the injection should be administered by a healthcare professional [2], but in practice, patients with adequate training and support have administered the injection at home under provider supervision.

HealthRX clinicians conduct full osteoporosis evaluations by telehealth for Oregon residents, order necessary labs and imaging through partnered Oregon laboratories, and coordinate with local pharmacies for injection administration. Telehealth visits through HealthRX are typically completed within five to seven business days of the initial request.

Cost Comparison: Brand Prolia vs. Compounded vs. Covered Options

The table below outlines the four main cost pathways an Oregon patient is likely to encounter in 2026. Dollar figures are per-injection (every 6 months) unless noted.

| Pathway | Per-Injection Cost (OR, 2026) | Key Requirement | |---|---|---| | Brand Prolia, no insurance | ~$1,500 | Cash at pharmacy | | Brand Prolia, commercial insurance + Amgen card | $0 (up to $13,000/year cap) | Commercial plan, enrolled in SupportPlus | | Brand Prolia, Oregon Medicaid (OHP) | $0 to $3 copay | PA approval required | | Brand Prolia, Medicare Part D (dual-eligible wraparound) | $0 to $10 | Dual-eligible status | | Compounded denosumab, 503A Oregon pharmacy | Variable, potentially much lower than $1,500 | Valid Rx, licensed pharmacy, regulatory caveats apply |

For the majority of Oregon patients with any insurance coverage, the Amgen savings card or Medicaid coverage brings the effective cost well below the $1,500 list price. The uninsured patient paying full cash is the clearest candidate for the Amgen Safety Net Foundation application or, after a prescriber discussion of the regulatory and clinical considerations, a compounded product from a licensed Oregon 503A pharmacy.

FRAX, DXA, and Clinical Thresholds: When Does Prolia Make Sense?

Before the question of cost arises, the clinical question is whether denosumab is indicated. The World Health Organization's FRAX tool, validated in a 2008 study published in Osteoporosis International, calculates 10-year fracture probability using bone density and clinical risk factors [18]. The National Osteoporosis Foundation (now part of the American Bone Health organization) recommends pharmacologic treatment when the 10-year hip fracture probability reaches 3% or above, or when the major osteoporotic fracture probability reaches 20% or above, or when the DXA T-score is -2.5 or below at any site [19].

Denosumab is specifically preferred over oral bisphosphonates when eGFR falls below 35 mL/min/1.73 m², because bisphosphonates accumulate in renal tissue at low GFR [4]. For a 68-year-old Oregon woman with a hip T-score of -2.8 and eGFR of 28, denosumab at 60 mg every six months is a clinically sound first-line choice, and navigating the cost pathway outlined in this article becomes the primary practical task.

The FREEDOM Extension study followed 4,550 patients for up to 10 years of continuous denosumab and found sustained vertebral fracture risk reduction with no evidence of a safety plateau [20]. That long-term data supports continued use beyond the five-year window sometimes applied to bisphosphonates.

Two hypocalcemia safety points apply specifically to Oregon's older population. First, adequate calcium intake (1,000 to 1 to 200 mg/day from food and supplements combined) and vitamin D (800 to 1 to 000 IU/day) should be confirmed before each injection [2]. Second, denosumab can cause significant hypocalcemia in patients with low baseline calcium or vitamin D, and the FDA label carries a boxed-adjacent warning for this risk. Baseline labs drawn at least two weeks before the injection date allow time to correct deficiencies.

Step-by-Step: Getting Prolia in Oregon With Minimal Out-of-Pocket Cost

The following sequence applies to most Oregon patients starting denosumab in 2026.

Step 1. Confirm the diagnosis. A DXA scan report showing T-score at or below -2.5, or documentation of a low-trauma fracture, is the foundation of any PA request and most savings-program applications. DXA is widely available in Oregon; most commercial plans cover it every two years under preventive benefits for women over 65 [21].

Step 2. Obtain a valid prescription. Any Oregon-licensed prescriber with DEA registration (or an Oregon telemedicine provider) may write the prescription. HealthRX provides telehealth consultations for Oregon residents seeking osteoporosis evaluation and denosumab prescribing.

Step 3. Determine your insurance category. Commercial insurance routes to the Amgen SupportPlus card. OHP routes to the PA process through your CCO. Medicare Part D routes to the pharmacy benefit manager's specialty tier, with dual-eligible wraparound if applicable. Uninsured routes to the Amgen Safety Net Foundation.

Step 4. Submit the PA if required. Provide the DXA report, fracture history, relevant labs (eGFR, calcium, 25-OH vitamin D), and any bisphosphonate trial documentation. OHP CCOs typically respond within 72 hours for standard PA requests; commercial plans are required by Oregon law to respond within 72 hours for non-urgent requests and 24 hours for urgent ones [22].

Step 5. Schedule the injection. Prolia must be administered subcutaneously, typically in the abdomen, upper thigh, or outer upper arm. The injection is brief and can be given in a primary care office, endocrinologist's office, infusion center, or in some cases at home with provider training. The next dose date should be scheduled before leaving the appointment, delaying beyond seven months from the prior injection raises rebound fracture risk significantly [5].

Step 6. Recheck labs before each dose. A serum calcium, eGFR, and 25-OH vitamin D level drawn four to six weeks before the scheduled injection date allows correction of any abnormalities before treatment. The FDA label recommends pre-dose correction of hypocalcemia [2].